Stifel Financial Corp Buys 3,676 Shares of GW Pharmaceuticals PLC (GWPH)

Stifel Financial Corp increased its stake in shares of GW Pharmaceuticals PLC (NASDAQ:GWPH) by 24.4% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 18,716 shares of the biopharmaceutical company’s stock after purchasing an additional 3,676 shares during the quarter. Stifel Financial Corp owned 0.07% of GW Pharmaceuticals PLC worth $1,885,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. Creative Planning lifted its holdings in shares of GW Pharmaceuticals PLC by 1.4% during the second quarter. Creative Planning now owns 2,532 shares of the biopharmaceutical company’s stock worth $254,000 after purchasing an additional 35 shares during the period. Advisor Group Inc. lifted its holdings in shares of GW Pharmaceuticals PLC by 10.7% during the second quarter. Advisor Group Inc. now owns 1,500 shares of the biopharmaceutical company’s stock worth $130,000 after purchasing an additional 145 shares during the period. Ameriprise Financial Inc. lifted its holdings in shares of GW Pharmaceuticals PLC by 8.5% during the second quarter. Ameriprise Financial Inc. now owns 2,064 shares of the biopharmaceutical company’s stock worth $207,000 after purchasing an additional 162 shares during the period. HighTower Advisors LLC lifted its holdings in shares of GW Pharmaceuticals PLC by 10.3% during the first quarter. HighTower Advisors LLC now owns 2,044 shares of the biopharmaceutical company’s stock worth $247,000 after purchasing an additional 191 shares during the period. Finally, United Capital Financial Advisers LLC lifted its holdings in shares of GW Pharmaceuticals PLC by 15.9% during the first quarter. United Capital Financial Advisers LLC now owns 2,448 shares of the biopharmaceutical company’s stock worth $296,000 after purchasing an additional 336 shares during the period. 75.06% of the stock is owned by hedge funds and other institutional investors.

GWPH has been the subject of several recent research reports. Zacks Investment Research downgraded GW Pharmaceuticals PLC from a “buy” rating to a “hold” rating in a report on Monday, July 24th. Goldman Sachs Group, Inc. (The) reaffirmed a “neutral” rating and set a $124.00 price target on shares of GW Pharmaceuticals PLC in a report on Friday, October 6th. ValuEngine raised GW Pharmaceuticals PLC from a “sell” rating to a “hold” rating in a report on Friday, September 1st. Evercore ISI initiated coverage on GW Pharmaceuticals PLC in a report on Wednesday, August 16th. They set an “outperform” rating and a $154.00 price target for the company. Finally, Cantor Fitzgerald set a $208.00 price target on GW Pharmaceuticals PLC and gave the stock a “buy” rating in a report on Tuesday, August 8th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $143.05.

GW Pharmaceuticals PLC (GWPH) opened at 111.25 on Tuesday. GW Pharmaceuticals PLC has a 52-week low of $92.65 and a 52-week high of $136.95. The stock’s market cap is $2.82 billion. The firm has a 50-day moving average price of $107.97 and a 200 day moving average price of $107.72.

GW Pharmaceuticals PLC (NASDAQ:GWPH) last announced its quarterly earnings results on Monday, August 7th. The biopharmaceutical company reported ($2.07) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.73) by ($0.34). GW Pharmaceuticals PLC had a negative return on equity of 28.80% and a negative net margin of 1,384.41%. The business had revenue of $3.14 million for the quarter, compared to analyst estimates of $2.10 million. During the same quarter last year, the firm posted ($0.05) EPS. Equities analysts anticipate that GW Pharmaceuticals PLC will post ($6.16) earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: “Stifel Financial Corp Buys 3,676 Shares

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. Creative Planning lifted its holdings in shares of GW Pharmaceuticals PLC by 1.4% during the second quarter. Creative Planning now owns 2,532 shares of the biopharmaceutical company’s stock worth $254,000 after purchasing an additional 35 shares during the period. Advisor Group Inc. lifted its holdings in shares of GW Pharmaceuticals PLC by 10.7% during the second quarter. Advisor Group Inc. now owns 1,500 shares of the biopharmaceutical company’s stock worth $130,000 after purchasing an additional 145 shares during the period. Ameriprise Financial Inc. lifted its holdings in shares of GW Pharmaceuticals PLC by 8.5% during the second quarter. Ameriprise Financial Inc. now owns 2,064 shares of the biopharmaceutical company’s stock worth $207,000 after purchasing an additional 162 shares during the period. HighTower Advisors LLC lifted its holdings in shares of GW Pharmaceuticals PLC by 10.3% during the first quarter. HighTower Advisors LLC now owns 2,044 shares of the biopharmaceutical company’s stock worth $247,000 after purchasing an additional 191 shares during the period. Finally, United Capital Financial Advisers LLC lifted its holdings in shares of GW Pharmaceuticals PLC by 15.9% during the first quarter. United Capital Financial Advisers LLC now owns 2,448 shares of the biopharmaceutical company’s stock worth $296,000 after purchasing an additional 336 shares during the period. 75.06% of the stock is owned by hedge funds and other institutional investors.

GWPH has been the subject of several recent research reports. Zacks Investment Research downgraded GW Pharmaceuticals PLC from a “buy” rating to a “hold” rating in a report on Monday, July 24th. Goldman Sachs Group, Inc. (The) reaffirmed a “neutral” rating and set a $124.00 price target on shares of GW Pharmaceuticals PLC in a report on Friday, October 6th. ValuEngine raised GW Pharmaceuticals PLC from a “sell” rating to a “hold” rating in a report on Friday, September 1st. Evercore ISI initiated coverage on GW Pharmaceuticals PLC in a report on Wednesday, August 16th. They set an “outperform” rating and a $154.00 price target for the company. Finally, Cantor Fitzgerald set a $208.00 price target on GW Pharmaceuticals PLC and gave the stock a “buy” rating in a report on Tuesday, August 8th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $143.05.

GW Pharmaceuticals PLC (GWPH) opened at 111.25 on Tuesday. GW Pharmaceuticals PLC has a 52-week low of $92.65 and a 52-week high of $136.95. The stock’s market cap is $2.82 billion. The firm has a 50-day moving average price of $107.97 and a 200 day moving average price of $107.72.

GW Pharmaceuticals PLC (NASDAQ:GWPH) last announced its quarterly earnings results on Monday, August 7th. The biopharmaceutical company reported ($2.07) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.73) by ($0.34). GW Pharmaceuticals PLC had a negative return on equity of 28.80% and a negative net margin of 1,384.41%. The business had revenue of $3.14 million for the quarter, compared to analyst estimates of $2.10 million. During the same quarter last year, the firm posted ($0.05) EPS. Equities analysts anticipate that GW Pharmaceuticals PLC will post ($6.16) earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: “Stifel Financial Corp Buys 3,676 Shares of GW Pharmaceuticals PLC (GWPH)” was reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this piece on another website, it was stolen and reposted in violation of U.S. and international copyright and trademark legislation. The original version of this piece can be viewed at https://ledgergazette.com/2017/10/17/stifel-financial-corp-buys-3676-shares-of-gw-pharmaceuticals-plc-gwph.html.

About GW Pharmaceuticals PLC

GW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company’s lead cannabinoid product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol (CBD).

Want to see what other hedge funds are holding GWPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GW Pharmaceuticals PLC (NASDAQ:GWPH).

Institutional Ownership by Quarter for GW Pharmaceuticals PLC (NASDAQ:GWPH)

Receive News & Ratings for GW Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply